NCT07110090View on ClinicalTrials.gov

Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
ThrombocytopeniaCancer
Interventions
BIOLOGICAL

Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002)

dosage form: Injection dosage: 10 mL/bag, 1×10⁷ cells/mL frequency: Each subject will be administered a single infusion of XJ-MK-001 at their respective enrolled dose level.

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences 17 Panjiayuan Nanli, Chaoyang District, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER